Cardiac-sparing whole lung IMRT in patients with pediatric tumors and lung metastasis: Final report of a prospective multicenter clinical trial Journal Article


Authors: Kalapurakal, J. A.; Gopalakrishnan, M.; Walterhouse, D. O.; Rigsby, C. K.; Rademaker, A.; Helenowski, I.; Kessel, S.; Morano, K.; Laurie, F.; Ulin, K.; Esiashvili, N.; Katzenstein, H.; Marcus, K.; Followill, D. S.; Wolden, S. L.; Mahajan, A.; Fitzgerald, T. J.
Article Title: Cardiac-sparing whole lung IMRT in patients with pediatric tumors and lung metastasis: Final report of a prospective multicenter clinical trial
Abstract: Purpose: Aprospective clinical trialwas conducted for patients undergoing cardiac sparing (CS) whole lung irradiation (WLI) using intensity modulated radiation therapy (IMRT). The 3 trial aims were (1) to demonstrate the feasibility of CS IMRT with real-time central quality control; (2) to determine the dosimetric advantages of WLI using IMRT compared with standard anteroposterior (AP) techniques; and (3) to determine acute tolerance and short-term efficacy after a protocol-mandated minimum 2-year follow-up for all patients. Methods and Materials: All patients underwent a 3-dimensional chest computed tomography scan and a contrast-enhanced 4-dimensional (4D) gated chest computed tomography scan using a standard gating device. The clinical target volume was the entire bilateral 3-dimensional lung volume, and the internal target volume was the 4D minimum intensity projection of both lungs. The internal target volume was expanded by 1 cm to get the planning target volume. All target volumes, cardiac contours, and treatment plans were centrally reviewed before treatment. The different cardiac volumes receiving percentages of prescribed radiation therapy (RT) doses on AP and IMRT WLI plans were estimated and compared. Results: The target 20 patients were accrued in 2 years. Median RT dose was 15 Gy. Real-time central quality assurance review and plan preapproval were obtained for all patients. WLI using IMRT was feasible in all patients. Compared with standard AP WLI, CS IMRT resulted in a statistically significant reduction in radiation doses to the whole heart, atria, ventricles, and coronaries. One child developed cardiac dysfunction and pulmonary restrictive disease 5.5 years after CS IMRT (15 Gy) and doxorubicin (375 mg/m(2)). The 2- and 3-year lung metastasis progression-free survival was 65% and 52%, respectively. Conclusions: We have demonstrated the feasibility of WLI using CS IMRT and confirmed the previously reported advantages of IMRT, including superior cardiac protection and superior dose coverage of 4D lung volumes. Further studies are required to establish the efficacy and safety of this irradiation technique. (C) 2018 Published by Elsevier Inc.
Keywords: doxorubicin; radiation; radiotherapy; diagnosis; irradiation; therapy; long-term; wilms-tumor; pulmonary metastases; cancer-study-group
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 103
Issue: 1
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2019-01-01
Start Page: 28
End Page: 37
Language: English
ACCESSION: WOS:000452811900009
DOI: 10.1016/j.ijrobp.2018.08.034
PROVIDER: wos
PUBMED: 30170102
Notes: Article -- Source: Wos
Altmetric Score
MSK Authors
  1. Suzanne L Wolden
    417 Wolden